Mergers & acquisitions
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the therapeutic, and the rest of Vitaeris’s assets.
Shares of Gilead Sciences jumped in pre-market trading this weekend following reports that the company has been approached by U.K. pharma giant AstraZeneca regarding a potential merger.
When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.
Roche hopes to advance the development of its own nanopore sequencer, which would use a new approach combining electronic and biological components to sequence DNA quickly and at low cost.
Xenotransplant company eGenesis snapped up a key manufacturing partner ICBiotec in order to vertically integrate its xeno-organ production capabilities.
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.
“It is the right time to have an excellent fully integrated, patient-focused biotechnology organization like PTC Therapeutics take over the late-stage development of CNSA-001 so that this promising compound becomes available to patients in the near future,” said Jonathan Reis, president and chief executive officer of Censa.
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.
Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.
Shares of New York-based Stemline Therapeutics skyrocketed more than 153% in premarket trading after Italy’s Menarini Group announced a $667 million acquisition of the oncology-focused company.
PRESS RELEASES